JNJ catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 3NCT03903835ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerKarolinska Institutet · Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingJNJCollaboratorAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 3NCT03767244A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical...Janssen Research & Development, LLC · Prostatic NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 3NCT05757869A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationJanssen Research & Development, LLC · Atrial FibrillationActive, not recruitingJNJLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2/Phase 3NCT05327114Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Janssen Research & Development, LLC · Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT04658862A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder...Janssen Research & Development, LLC · Urinary Bladder NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT06559306Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia...Janssen Research & Development, LLC · Depressive Disorder, MajorRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT01804686A Long-term Extension Study of PCI-32765 (Ibrutinib)Janssen Research & Development, LLC · Chronic Lymphocytic LeukemiaActive, not recruitingJNJLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 31, 2027Sponsor estimate | NCT05047172Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular AtherostenosisUniversity of Florida · Intracranial Arteriosclerosis | AZNCollaboratorJNJCollaborator | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT05179876A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionActelion · Hypertension, Pulmonary | JNJLead | Phase 3 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 31, 2027Sponsor estimatePhase 3NCT05047172Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular AtherostenosisUniversity of Florida · Intracranial ArteriosclerosisActive, not recruitingAZNCollaboratorJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 3NCT05179876A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionActelion · Hypertension, PulmonaryRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 4, 2027Sponsor estimate | NCT06741969Nipocalimab in Moderate to Severe Sjogren's DiseaseJanssen Research & Development, LLC · Sjogrens Syndrome | JNJLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Feb 10, 2027Sponsor estimate | NCT06260163A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisJanssen Research & Development, LLC · Colitis, Ulcerative | JNJLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Feb 10, 2027Sponsor estimate | NCT06807424A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With...Janssen Research & Development, LLC · Arthritis, Psoriatic | JNJLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 4, 2027Sponsor estimatePhase 3NCT06741969Nipocalimab in Moderate to Severe Sjogren's DiseaseJanssen Research & Development, LLC · Sjogrens SyndromeActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2027Sponsor estimatePhase 3NCT06260163A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisJanssen Research & Development, LLC · Colitis, UlcerativeActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2027Sponsor estimatePhase 3NCT06807424A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With...Janssen Research & Development, LLC · Arthritis, PsoriaticActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.